Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | GUSB | P08236 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11702408 | 0.82 | ALDH1A1 (0.46) | ALDH1A1MAPK1TDP1BCHEGUSB | |
| Water SCHEMBL11418867 | 0.80 | ALDH1A1 (0.44) | ALDH1A1MAPK1TDP1BCHEGUSB | |
| SCHEMBL2652860 | 0.75 | ALDH1A1 (0.50) | ALDH1A1MAPK1TDP1 | |
| SCHEMBL2651865 | 0.73 | ALDH1A1 (0.44) | ALDH1A1CA1CA2 | |
| SCHEMBL2650858 | 0.73 | CES2 (0.50) | ALDH1A1MAPK1TDP1BCHEERN1 | |
| SCHEMBL420969 | 0.70 | ALDH1A1 (0.59) | ALDH1A1MAPK1TDP1BCHEGUSB | |
| SCHEMBL19183590 | 0.68 | ALDH1A1 (0.41) | ALDH1A1 | |
| Water SCHEMBL11415614 | 0.68 | HNF4A (0.47) | ALDH1A1MAPK1TDP1 | |
| Water SCHEMBL11409301 | 0.68 | HNF4A (0.47) | ALDH1A1MAPK1TDP1 | |
| SCHEMBL1200734 | 0.67 | ALDH1A1 (0.40) | ALDH1A1MAPK1TDP1BCHEGUSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349856-B1 | ISOINDOLIN-1-ONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | EP | disclosed |
| EP-1349856-A2 | ISOINDOLIN-1-ONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-08 | — | — | EP | disclosed |
| US-6482951-B2 | ISOINDOLIN-1-ONE-SUBSTITUTED PROPIONAMIDE GLUCOKINASE ACTIVATORS WHICH INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES | HOFFMANN-LA ROCHE INC. | 2002-11-19 | — | — | US | disclosed |
| US-20020082260-A1 | Isoindolin-1-one glucokinase activators | GUERTIN KEVIN RICHARD (US) | 2002-06-27 | — | — | US | disclosed |
| WO-2002048106-A2 | ISOINDOLIN-1-ONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA-ROCHE AG (CH) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082260-A1 | Isoindolin-1-one glucokinase activators | GCKR, GCK, PGK2 | ALDH1A1 1838/4885MAPK1 937/4885TDP1 3375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.